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ABSTRACT
The plasticity of myeloid cells is illustrated by a
diversity of functions including their role as effec-
tors of innate immunity as macrophages (MACs)
and bone remodelling as osteoclasts (OCs). TET2,
a methylcytosine dioxygenase highly expressed
in these cells and frequently mutated in myeloid
leukemias, may be a key contributor to this plas-
ticity. Through transcriptomic and epigenomic anal-
yses, we investigated 5-methylcytosine (5mC), 5-
hydroxymethylcytosine (5hmC) and gene expression
changes in two divergent terminal myeloid differenti-
ation processes, namely MAC and OC differentiation.
MACs and OCs undergo highly similar 5hmC and
5mC changes, despite their wide differences in gene
expression. Many TET2- and thymine-DNA glycosy-
lase (TDG)-dependent 5mC and 5hmC changes di-
rectly activate the common terminal myeloid differen-
tiation programme. However, the acquisition of differ-
ential features between MACs and OCs also depends
on TET2/TDG. In fact, 5mC oxidation precedes differ-
ential histone modification changes between MACs
and OCs. TET2 and TDG downregulation impairs the
acquisition of such differential histone modification
and expression patterns at MAC-/OC-specific genes.
We prove that the histone H3K4 methyltransferase
SETD1A is differentially recruited between MACs and
OCs in a TET2-dependent manner. We demonstrate a
novel role of these enzymes in the establishment of
specific elements of identity and function in terminal
myeloid differentiation.
INTRODUCTION
Myeloid cells undergo terminal differentiation processes
in response to a variety of external stimuli that are ex-
posed to in the bone marrow, blood and tissues. Myeloid
terminal differentiation generates a great diversity of cell
types including various macrophage types, inflammatory
dendritic cells, osteoclasts and microglia among others. In
these processes, the acquisition of a specific phenotype re-
quires the exquisite regulation of gene expression, which
depends on the interplay of receptors to extracellular sig-
nals, downstream signalling pathways and many different
transcription and epigenetic factors. Myeloid cells express
high levels of several epigenetic enzymes, like TET2 and
DNMT3A, related to the modification of cytosines. This
fact, together with the high frequency of mutations of these
two enzymes in myeloid leukemias (1–3), indicates a key
role of these processes in the specification of myeloid iden-
tity. Cytosine methylation is a major epigenetic mark asso-
ciated with gene repression or activation and stability, de-
pending on the genomic context (4). Cytosines can be not
only methylated in the form of 5-methylcytosine (5mC), but
also subsequently oxidized by Ten-Eleven-Translocation
(TET) methylcytosine dioxygenases, thereby generating
5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC)
and 5-carboxylcytosine (5caC). The latter two are excised
by thymine DNA glycosylase (TDG), triggering base ex-
cision repair that leads to the restitution of unmethylated
cytosine (5). Alternative active DNA demethylation path-
ways have been reported involving the cytidine deaminase
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AID (6–8) or other DNA glycosylases (9,10). Methylated
cytosines are specifically recognized by nuclear factors such
as methyl-CpG binding domain proteins or Kaiso (11,12).
These nuclear factors recruit histone modification enzymes
to 5mC and locally modify the chromatin modification sta-
tus (13,14). There is still some controversy about whether
oxidized cytosines (5hmC, 5fC and 5caC) also have direct
functional effects or merely act as intermediates. The lat-
ter two cytosine-oxidized forms, 5fC and 5caC, are present
at low proportions, probably due to their instability or the
fast turnover of the subsequent enzymatic steps (15). How-
ever, 5hmC is relatively stable (16) and is differentially rec-
ognized by certain nuclear factors (17–19). This suggests
that it might be an epigenetic mark on its own merit. Re-
cent data indicate that at least 5fC could also be a stable
modification in mammals (20) with tissue-specific roles by
recruiting specific transcriptional and chromatin regulators
(19,21) or targeting active enhancers (20,22).
It is accepted that gene activation or transcriptional prim-
ing results from the tight crosstalk between cytosine methy-
lation and histone modifications (23). It is likely not only
that cytosine methylation interplays with complexes target-
ing histone modification but also that 5hmC and other ox-
idized cytosine forms have such effects. In connection with
this, TET1–3 and TDG may not only have a role in active
demethylation but also in modulating interactions between
local chromatin and histone modification complexes based
on the oxidation status of cytosines (24–26).
As aforementioned, myeloid cells undergo terminal dif-
ferentiation processes that lead to the generation of vari-
ous specialized cell types. These processes can be recapitu-
lated in vitro from primary humanMOs using related cock-
tails of growth factors such as GM-CSF or M-CSF, which
lead to macrophage (MAC) differentiation. Additional cy-
tokines like IL-4 andRANKL redirectMACdifferentiation
towards dendritic cell or osteoclast (OC) formation respec-
tively. TET2-mediated oxidation of 5mC followed by TDG-
and base excision repair-mediated recovery of unmethylated
cytosines is essential in these monocyte (MO)-related differ-
entiation processes (27,28). TET2 is targeted to specific ge-
nomic sites through specific transcription factors like PU.1
(29) or through IL-4-JAK3-STAT6 signalling (28). How-
ever, we know little about the functional contribution of
TET2 and TDG in these myeloid differentiation processes
and its contribution to the final phenotype beyond the ef-
fects on sets of genes.
To address these aspects, we first determined 5mC, 5hmC
and expression changes over time in two related myeloid
differentiation processes, namely MAC and OC differen-
tiation. Differentiation to functional MACs and OCs is
achieved in vitro using M-CSF in both cases, and RANKL
is necessary for efficient differentiation ofOCs.Despite their
wide differences in gene expression, we observed that MAC
and OC differentiation displayed very similar 5mC and
5hmC changes over time, indicating that RANKL makes a
negligible contribution to the acquisition of DNA methy-
lation profiles and that they mostly depend on M-CSF.
By downregulating TET2 and TDG, we demonstrated that
they are necessary for the acquisition of the final functional
features of both MACs and OCs. In fact, we observed that
a TET2- and TDG-mediated demethylation step is required
before the differential acquisition of histone modifications
like trimethylation of lysine 4 of histoneH3 (H3K4me3) and
acetylation of histone H3 (H3Ac) in genes that are differ-
entially expressed between MACs and OCs. We also prove
that TET2 is required to allow differential recruitment of
theH3K4methyltransferase SETD1A toOC-specific genes.
This supports the notion that TET2 and TDGnot only play
a role in demethylating genes but also in ensuring the estab-
lishment of subsequent modification by histone modifica-
tions at specific genomic sites.
MATERIALS AND METHODS
Differentiation of MACs and OCs from peripheral blood
mononuclear cells
Human blood samples used in this study came from anony-
mous donors via the Catalan Blood and Tissue Bank
(CBTB) as buffy coats. All donors received oral and writ-
ten information and signed a consent form prior to any
donation at the CBTB. The CBTB follows the princi-
ples set out in the World Medical Association (WMA)
Declaration of Helsinki. The blood was carefully layered
on a Ficoll–Paque gradient (Amersham, Buckinghamshire,
UK) and centrifuged at 800 g for 30 min without brak-
ing. After centrifugation, peripheral blood mononuclear
cells (PBMCs) at the interface between the plasma and the
Ficoll–Paque gradient were collected andwashed twicewith
ice-cold phosphate-buffered saline, followed by centrifuga-
tion at 300 g for 5 min. Pure CD14+ cells were isolated
from PBMCs using positive selection with MACS mag-
netic CD14 antibody (Miltenyi Biotec, Bergisch Gladbach,
Germany). Cells were attached to the plate for 30 min in
free-serum media and then cultured in -minimal essential
medium (-MEM, Glutamax no nucleosides) (Invitrogen,
Carlsbad, CA, USA) containing 10% fetal bovine serum,
100 units/ml penicillin, 100 g/ml streptomycin and an-
timycotic and supplemented with 25 ng/ml human M-CSF
(PeproTech EC, London, UK) for MAC differentiation. In
the case of OC differentiation, we added soluble RANKL
(50 ng/ml) (PeproTech EC, London, UK) in addition toM-
CSF. Cells were seeded at a density of 1 × 106cells/well in
12-well plates and 1 × 105 cells/well in 96-well plates and
cultured for 5 or 20 days (unless otherwise noted); medium
and cytokines were changed twice a week.
Bisulfite (BS) and oxidative-bisulfite (oxBS) treatment
DNA was isolated by proteinase K protocol. BS and oxBS
conversion were performed as detailed in Booth et al. (30).
DNA samples (∼1 g) were first purified with AMPure®
XP beads (1.6× volumes) (Beckman Coulter Inc., CA,
USA), washed with 80% ethanol and eluted in MilliQ-
water. At this point, each DNA sample was split into two
aliquots and processed through either the BS or oxBS treat-
ment. The oxBS samples were purified via buffer exchange
with Micro Bio-Spin® P-6 SSC columns (Bio-Rad Labo-
ratories, Inc., USA) and eluted in ∼22 l MilliQ-water. Af-
ter DNA denaturation with 1.25 l NaOH (1M) for 30 min
in a shaking incubator at 37◦C, DNA was oxidized with 2
l KRuO4 (15 mM) (Alfa Aesar, Germany) for 60 min in
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an ice-water bath (vortexing the reaction twice) and cen-
trifuged at 16 000 g for 15 min. Finally, both DNA and ox-
idized DNA were BS converted using the EZ DNAMethy-
lation™ kit (Zymo Research, CA, USA). BS- and oxBS-
modified DNA samples were then hybridized on the In-
finium 450K chip or subjected to PCR amplification fol-
lowed by pyrosequencing.
A spike-in 100-oligomer amplified with dhmCTPs (Bio-
line) was added to the DNA sample prior to preoxidation
and interrogated by pyrosequencing to get accurate quan-
tification of conversion efficiency (mean > 90%). Spike-in
and pyrosequencing primer sequences are listed in Supple-
mentary Table S1.
DNA methylation profiling using universal bead arrays
Infinium HumanMethylation450 BeadChips (Illumina,
Inc., San Diego, CA, USA) were used to analyse 5mC and
5hmC levels. This array interrogates >485 000 methylation
sites per sample at single-nucleotide resolution. This encom-
passes 99% ofRefSeq genes, with an average of 17 CpG sites
per gene region distributed across the promoter, 5′UTR,
the first exon, the gene body and 3′UTR. It covers 96%
of CpG islands, with additional coverage in CpG island
shores and the regions flanking them. DNA samples were
bisulfite-converted using EZ DNA methylation kits (Zymo
Research, Orange, CA, USA). After bisulfite treatment, the
remaining assay steps were performed following the specifi-
cations by themanufacturer. Arrays were hybridised using a
temperature gradient program and imaged using a BeadAr-
ray Reader (Illumina, Inc.). Image processing and intensity
data extraction software and procedures used were as previ-
ously described. Each methylation data point was obtained
from a combination of the Cy3 and Cy5 fluorescent intensi-
ties from the M (methylated) and U (unmethylated) alleles.
Background intensity correction was not used but fluores-
cent intensities close to zerowere thresholded. For represen-
tation and further analysis we used beta andM values. Beta
is the ratio of the methylated probe intensity to the over-
all intensity (the sum of the methylated and unmethylated
probe intensities). Beta values range from 0 to 1, in which 0
is no methylation and 1 is complete methylation. Beta val-
ues show severe heteroscedasticity for highly methylated or
unmethylated CpG sites and are therefore logistically trans-
formed toM values, which were used to obtain FDR. Beta
values were used to derive heatmaps and to compare DNA
methylation percentages from bisulfite pyrosequencing ex-
periments. For statistical purposes, the use of M values is
more appropriate.
Quality control and data normalization
Methylation array data were processed in R using meth-
ods from the Bioconductor libraries minfi, lumi and limma.
Data quality was assessed using the standard pipeline
from the minfi package and no severe outliers were de-
tected, although the BS and oxBS treated samples were
observed to be distinct and were normalized separately.
The normalization strategy was chosen comparing all avail-
able methods from the minfi package for lowest intra-
group and highest inter-group variation. The data were
quantile-normalized using a stratification approach includ-
ing probetype (I, II), methylation ((un)-methylated), chro-
mosome type (auto/gono-somes), sex (male/female) and
CpG-region (CpG island, shore, shelf, open sea regions).
After normalization, 5mC levels were derived from the
oxBS data as beta values, while 5hmC levels were calcu-
lated by subtracting the oxBSM values from the BSM val-
ues using the same biological replicate. After subtraction,
5hmCM values were again quantile normalized and trans-
formed to beta values. Negative 5hmC beta values were set
to zero. The appropriate model was determined compar-
ing different linear models for the 10K probes with high-
est variance across all individual data points (n = 15) us-
ing the selectModel function (limma package). Thirty two
(42%) of CpG probes were best represented by the most
complex model: methylation ∼ individual + differentiation
stage + error for the methylation and hydroxymethylation
data, respectively. The data were analyzed using an eBayes-
moderated t-test, available in the limma package, using the
most complex model for all probes. To reduce the number
of statistical tests we excluded probes that were unmethy-
lated or fully methylated in all groups (0.15 > average beta
> 0.8).
In this study, we considered a probe to be differen-
tially methylated if it showed ≥2-fold (hypermethylation)
or≤0.5-fold (hypomethylation) changes. Additionally, only
statistically significant tests (P < 0.05 and FDR < 0.05)
were considered. For candidate gene selection we added the
requirement for the difference in beta values to be at least
20% for the methylation and at least 10% for the hydrox-
ymethylation data.
In vitroOC formation, pit formation and phagocytosis assay
The presence of OCs was checked at specified time points
by tartrate-resistant acid phosphatase (TRAP) staining us-
ing the Leukocyte Acid Phosphatase Assay Kit (Sigma-
Aldrich, Gillingham, UK) according to the manufacturer’s
instructions. TRAP+ multinucleated cells (≥3 nuclei) were
considered as OCs and represented as a percentage of total
cells (three randomly selected fields/well).To measure OC
activity, MOs were seeded on calcium-coated wells (Corn-
ing, NY, USA) in osteoclastogenic medium for 20 days, and
resorption pit area was calculated using the Adobe Photo-
shop histogram function (Adobe Photoshop CS5).
To quantify the phagocytic activity,MACs and OCs were
detached using Cell Dissociation Solution Non-enzymatic
(Sigma-Aldrich) and 50 × 103 cells were incubated with
pHrodo™ redE. coliBioParticles® (Life Technologies, Ore-
gon, USA) for 30 min at 37◦C. Cells incubated on ice with
BioParticles® were used as negative controls. Engulfed
BioParticles® became fluorescent due to the acidic envi-
ronment of the phagosome after phagocytosis and were de-
tected at 585 nm by flow cytometry.
Flow cytometry analysis
Cells were detached using Cell Dissociation Solution Non-
enzymatic (Sigma-Aldrich) and stained with fluorochrome-
conjugated antibodies against CD163-FITC, CD11b-APC
(both from BioLegend), CD206-FITC (BD BioSciences),
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MSR1-Alexa Fluor® 700 (R&D Systems, MN, USA) and
CD33-PE (eBioscience) at 5 and 20 days after M-CSF or
M-CSF/RANKL stimulation. Cells (50 × 103) were ac-
quired using a Gallios Flow Cytometer (Beckman Coul-
ter, Pasadena, CA, USA) and analyzed by FlowJo software
(Tree Star, Inc., Ashland, OR, USA).
Quantitative real-time PCR
Total RNA was isolated using TriZOL reagent (Qi-
agen). Reverse transcription was performed using the
Transcriptor First Strand cDNA Synthesis Kit (Roche,
Basel, Switzerland) according to manufacturer’s instruc-
tions. qRT-PCRwas done on a LightCycler® 480 II System
using LightCycler® 480 SYBR Green Mix (Roche). Reac-
tions were performed in triplicate for both the target and the
housekeeping gene ribosomal protein L38 (RPL38) used for
normalization. Relative quantification of the target gene ex-
pression was calculated by the comparative threshold cycle
(Ct) method. Primer sequences are listed in Supplementary
Table S1.
BS and oxBS pyrosequencing
DNA from BS and oxBS conversion (∼20–30 ng) was
used as a template in each subsequent PCR. Primers for
PCR amplification and sequencing were designed with the
PyroMark® Assay Design 2.0 software (Qiagen GmbH,
Hilden, Germany). PCRs were performed with the Hot-
Start Taq DNA polymerase PCR kit (Qiagen), and the
success of amplification was assessed by agarose gel elec-
trophoresis. PCR products were pyrosequenced with the
Pyromark Q24 system (Qiagen). 5hmC levels were calcu-
lated by substraction of oxBS from BS methylation calls.
All primer sequences are listed in Supplementary Table S1.
Gene expression arrays
Expression studies were performed using the Agilent plat-
form following manufacturer’s instructions. Briefly, 100 ng
RNA extracted with TriZOL from MOs, MACs and OCs
hybridized to a SurePrint G3 Human Gene Expression Ar-
ray (Agilent Technologies, CA, USA). Probe intensity nor-
malization and downstream analysis were obtained using
statistical analysis language R in combination with Biocon-
ductor repository functions (http://bioconductor.org).Data
normalization was followed by probe identity filtering, un-
der strong statistical confidence thresholds (P< 0.01; FDR
< 0.05; FC < 0.5 and FC > 2 for downregulated and up-
regulated respectively). Finally, comparison of expression
and DNA methylation and hydroxymethylation data were
performed by applying custom R scripting. To test for the
association of gene expression and 5mC/5hmC we calcu-
lated the Pearson correlation coefficient using outlier cor-
rected data. In detail, we fit a linearmodel and removed data
points with Cooks distance measures greater than twice the
median Cooks distance.
Gene ontology analysis
Gene ontology (GO) was analyzed with the FatiGO tool
(31), which uses Fisher’s exact test to detect significant over-
representation ofGO terms in one of the sets (list of selected
genes) with respect to the other (the rest of the genome).
Multiple test correction to account for the multiple hy-
potheses tested (one for each GO term) was applied to re-
duce false-positive results. GO terms with adjusted values
of P < 0.05 were considered significant.
Enhancer identification and HOMER analysis
Enhancers were identified using the FANTOM5 Tran-
scribed Enhancer Atlas that is available online (http://
fantom.gsc.riken.jp/5/top). This tool allows the identifica-
tion of distinct bidirectional Cap Analysis of Gene Ex-
pression (CAGE) patterns to predict the existence of en-
hancers in a variety of human cells including monocytes.
The search for transcription factor sequence recognition
motifs was performed using HOMER software v4.5. To de-
termine the relative enrichment of known motifs in CpGs
mapping in enchancer regions for each cluster, sequence
contained in 500-bp windows was searched against a se-
lected background of windows that were adjusted to have
equal GC content and the same number of CpGs.
Immunoblotting
Electrophoresis and immunoblotting were performed ac-
cording to standard procedures. The blots were developed
using the ECLdetection kit (AmershamPharmacia Biotech
Inc., NJ, USA). Primary antibodies were directed against:
TET2 (Diagenode,Ref: C15200179), TDG (kindly provided
by Dr P. Scha¨r, from the University of Basel), histone H3
(Abcam, Ref: ab1791) and actin (Abcam, Ref: ab6276).
Chromatin immunoprecipitation (ChIP) assays
For ChIP assays, MOs, MACs and OCs were crosslinked
at specified differentiation day with 1% formaldehyde and
subjected to immunoprecipitation after sonication. ChIP
experiments were performed using the LowCell# ChIP
kit™ protein A (Diagenode, Lie`ge, Belgium) and antibod-
ies against acetylated Lys at the N-t of histone H3 (H3Ac)
(Millipore, Ref: 06-599), trimethylated Lys 4 of histone H3
(H3K4me3) (Millipore, Ref: CS200580) and histone H3
Lys 4 methyltransferase SETD1A (Abcam, Ref: ab70378).
Analysis was performed by real-time quantitative PCR.
Data are represented as the ratio of the ‘bound’ fraction of
the histone modification antibody with respect to the input.
ChIP primers were designed for the areas flanking differ-
entially methylated CpGs and their sequences are shown in
Supplementary Table S1.
Transfection of primary human MOs
We used ON-TARGETplus siRNAs (GEHealthcare Dhar-
macon) against TET2, TDG and AICDA to perform
knockdown experiments in peripheral blood MOs. We also
used ON-TARGETplus Non-targeting Control Pool as a
negative control. We transfected MOs with siRNAs using
Lipofectamine 3000Reagent (ThermoFisher Scientific Co.,
Carlsbad, CA, USA). We repeated transfections every 3
days after starting the culture. We examined the levels of
the target factors by qRT-PCR and western blot assays at
specified times.
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Statistical analysis
Each assay was performed at least three times using MOs
from different individuals. Quantitative data are expressed
as mean ± SEM. Data were analyzed using GraphPad
prism software Version 6 (GraphPad). Statistical compar-
isons were performed using the nonparametric Mann–
Whitney U test (2 groups) and Kruskal-Wallis with Mann–
WhitneyU post-hoc test, and values of *P< 0.05 were con-
sidered significant (GraphPad Software Inc., CA, USA).
RESULTS
MACs andOCs display almost identical 5mC and 5hmC pro-
files that depend on M-CSF stimulation
To investigate the role of TET2-mediated changes in termi-
nal myeloid differentiation, we first performed in parallel
mRNA, 5mC and 5hmC profiling of two related myeloid
differentiation processes, specifically MAC and OC differ-
entiation, which produce two morphologically and func-
tionally distinct cell types. MO-to-MAC and MO-to-OC
differentiation depend on M-CSF stimulation, and the lat-
ter requires the additional factor RANKL (Figure 1A).
Specifically, we analyzed MOs stimulated for 5 and 20 days
with M-CSF and M-CSF/RANKL.
TRAP staining, dentin resorption and phagocytic activ-
ity assays confirmed the acquisition of function. At 5 days,
both M-CSF and M-CSF+RANKL cultures were stained
positive for TRAP and had a similar appearance contain-
ing a high number of spindle-like cells without displaying
cell fusion (Supplementary Figure S1A). However, at 20
days only MOs incubated with both M-CSF and RANKL
differentiated into giant polykaryons (>80% with 3–20 nu-
clei) with a large cytoplasmic spreading and resorption ac-
tivity, as expected for OCs (Figure 1B). In contrast, only
a small number (<10%) of M-CSF treated MOs displayed
cell fusion (3–5 nuclei) as previously reported (32). The
phagocytic activity of MOs treated with M-CSF for 20
days was significantly higher than in those treated with
bothM-CSFandRANKL (Figure 1C). FACS analysis con-
firmed the existence of differential surface marker staining
in MOs, MACs and OCs. The scavenger receptor CD163
showed significantly higher expression levels inMACs com-
pared to OCs after 20 days of cytokine stimulation, whereas
M2 macrophage markers (CD206 andMSR1) and myeloid
markers (CD33 and CD11b) were increased in both cell
types during the differentiation process (Figure 1D).
Expression profiling of MACs and OCs at 5 and 20
days allowed the identification of transcripts that are dif-
ferentially expressed (Supplementary Figure S1B). Specifi-
cally, we observed upregulation of 4339 and 4513 genes and
downregulation of 3110 and 3098 genes 5 days after stim-
ulation with M-CSF- and M-CSF/RANKL, respectively
(>2-fold change or <0.5-fold change; P < 0.01; FDR <
0.05) (Supplementary Table S2). The comparison between
MOs stimulated for 5 and 20 days showed that 1342 and
1241 were upregulated, and 1064 and 1370 were downreg-
ulated with M-CSF and M-CSF/RANKL stimulation, re-
spectively (Supplementary Table S2), indicating that major
expression changes occurred during the first 5 days of dif-
ferentiation. In this analysis, we also observed differences
in gene expression between MACs and OCs at 5 and 20
days (Figure 1E and Supplementary Figure S1C). Differ-
ences were noted in genes such as FOLR2, IL10, C1QC and
VSIG4 (involved in the modulation of the inflammatory re-
sponse), which show higher expression in MACs compared
to OCs (33). Upregulated genes in OCs included CTSK,
ADAMTS14 and MMP1 (encoding for proteases involved
in bonematrix resorption), whereas the transcription factor
IRF8 was specifically downregulated in OCs, in accordance
with its repressive role in this context (34) (Figure 1F). In
brief, all these analyses confirmed the wide range of differ-
ences between these two differentiated cell types.
For 5mC and 5hmC profiling, we hybridized BS- and
oxBS-treated DNA samples (MOs, 5 days MACs and pre-
OCs, 20 days MACs and OCs) on bead arrays. Statistical
analysis of the combined data from the five sets of samples
( > 0.2; P < 0.05; FDR < 0.05 for 5mC;  > 0.1; P <
0.05 for 5hmC) (Supplementary Table S3 and Supplemen-
tary Table S4) yielded several initial conclusions, which are
summarized as follows: (i) the patterns of both 5mC and
5hmC of M-CSF- and M-CSF/RANKL-stimulated MOs
are highly similar at both 5 and 20 days, indicating that
RANKL makes a small contribution to the acquisition of
changes in the 5mC and 5hmC patterns (Figure 2A and E);
(ii) both MAC and OC differentiation predominantly un-
dergo loss of 5mC (Figure 2A), whereas gains of 5mC only
occur at late stages in both processes (Figure 2A); (iii) 5hmC
dynamics are more complex than those of 5mC, and 5hmC
changes include groups of CpG sites that lose 5hmC, in con-
trast to other groups of CpG-containing sequences that un-
dergo transient or permanent gains of 5hmC (Figure 2E).
Firstly, RANKL did not have a drastic effect on the ac-
quisition of differential methylation patterns (Figure 2A) in
contrast to the effects observed in similar processes by other
cytokines like IL-4 (28). By decreasing the threshold ( >
0.1) we were able to identify around 55 CpG hypomethy-
lated in OCs with respect to MACs and only 6 CpG sites
were hypermethylated in OC with respect to MACs at 20
days following M-CSF (and RANKL) stimulation (Sup-
plementary Figure S2A and Supplementary Table S5). The
majority of these changes are located in open sea regions
encompassing gene body and intergenic regions (Supple-
mentary Figure S2B, left). GO analysis identified signifi-
cant enrichment in functions related to OC biology, (Sup-
plementary Figure S2B, right) and HOMER analysis re-
vealed putative TF binding motifs such as Jun/Fos, BATF
or ZNF528 (Supplementary Figure S2C). These small 5mC
changes across cell differentiation affected genes involved
in proteolytic activity (CTSK, ADAMTS8, HYAL2) and re-
lated with NF-B regulation (URGCP and WDFY1 as ac-
tivators and ZNF366, SLC39A1 and CUX1 as inhibitors)
(35–37). Bisulfite pyrosequencing of representative CpGs
(CTSK and ZNF366) confirmed their demethylation in
OCs, but also some partial demethylation in MACs (Sup-
plementary Figure S2D), suggesting that the observed dif-
ferences may be indirect rather than the result of specific
targeting by elements downstream of RANKL.Most DNA
methylation changes in both MAC and OC differentiation
therefore appeared to depend onM-CSF,which, upon inter-
action with its receptorM-CSFR, mediates downstream ef-
fector functions. In fact, treatment of MACs and OCs with
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Figure 1. M-CSF and RANKL drive differential gene expression and function in MACs and OCs. (A) Schematic diagram depicting the two cell differ-
entiation processes. Peripheral blood MOs are either stimulated with M-CSF or M-CSF/RANKL to generate MACs and OCs, respectively. At 5 days,
M-CSF cells are fully differentiated into MACs, whereas M-CSF/RANKL cells are pre-OCs (not displaying cell fusion); at 20 days, OCs have achieved
full differentiation. (B) TRAP staining and pit resorption analysis of M-CSF- and M-CSF/RANKL-treated cells at 20 days. At the bottom, a bar graph
representing the percentage of OCs (TRAP+ cells with three or more nuclei) (left) and a bar graph representing the percentage of the resorption lacunae
area (right) are presented. (C) Phagocytosis assay showing the fluorescence emission of engulfed bacteria byMACs and OCs at 5 and 20 days. (D) Analysis
of MAC and OC surface markers (CD163, CD206, MSR1, CD11b and CD33) by flow cytometry. Histograms show the percentage of positive cells for
each marker (left) and graphs show the median fluorescence intensity (MFI) for selected surface markers (right). (E) Heatmap including all the genes
displaying significant expression changes between MAC and OC at 5 and 20 days (>2-fold or <0.5-fold change; P < 0.01 and FDR < 0.05). A scale is
shown at the bottom, wherein expression values range from -3 (lower expression levels, blue) to +3 (higher expression levels, red). (F) Expression of MAC
(FOLR2, IL10, C1QC, VSIG4, LYVE1) and OC (CTSK, ADAMTS14, MMP1, IRF8, MET) markers, checked by quantitative RT-PCR at 5 and 20 days
in comparison with MOs. Quantitative RT-PCR data relative to RPL38. Graphs represent mean values from MACs and OCs derived from MOs of three
healthy donors ± SEM. *P < 0.05 indicates significant differences between M-CSF and M-CSF+RANKL-treated cultures.
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Figure 2. High-throughput 5mC and 5hmC profiling inMOs followingM-CSF andM-CSF/RANKL exposure leading toMACs andOCs respectively. (A)
Heatmap including the 5mCdata for three paired samples ofMOs,MACs andOCs (D1,D2,D3) harvested on days 5 and 20. The heatmap includes all CpG-
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GW2580, anM-CSFR inhibitor, led to a significant impair-
ment of demethylation changes in selected genes including
FOXP1 and IL10 (Supplementary Figure S2E).
Different 5hmC dynamics during MAC and OC differentia-
tion are associated with loss of 5mC
The analysis of the 5mC patterns in MOs following 5 and
20 days of M-CSF or M-CSF/RANKL exposure revealed
the existence of three clusters of CpG sites (Figure 2A):
group 1–5mC, corresponding to 858CpG sites that undergo
a rapid loss of 5mC; group 2–5mC, comprises of 74 CpG
sites that undergo a slow loss of 5mC, which was only signif-
icant at day 20; group 3–5mC, a cluster of 225CpG sites that
undergo gains of 5mC (Supplementary Table S3). This lat-
ter finding showed that gains of DNA methylation are not
exclusive to OCs (28,29) but also occur in MACs when M-
CSF stimulation is maintained for several weeks. We then
investigated the corresponding 5hmC levels for the same
CpG sites in the groups that displayed differential 5mC pro-
files during the two differentiation processes and observed
that the CpGs that underwent a slow loss of 5mC achieved
a significant increase in 5hmC in both MACs and OCs at
5 and 20 days (Figure 2B). As expected, hypermethylated
CpGs exhibited the lowest levels of 5hmC (Figure 2B). In
general, changes in 5mC are not necessarily associated with
changes in 5hmC for the indicated times of the differentia-
tion process.
When focusing the analysis on 5hmC changes (Figure
2E), we also observed the appearance of three groups of
CpG sites: group 1–5hmC, corresponding to a group of
CpG sites that display higher levels of 5hmC in MOs and
undergo loss of 5hmC over time at 5 and 20 days; group
2–5hmC are CpG sites that display a transient increase in
5hmC at 5 days followed by a decrease at 20 days; group
3–5hmC is a cluster of CpG sites that undergo increases in
5hmC and remain relatively high over time (Figure 2E and
Supplementary Table S4). Groups 1 and 3 represent CpG
sites that have stable high levels of 5hmC in MOs or in the
finalMAC/OCdifferentiated state, suggesting that 5hmC is
a stable epigenetic mark. We observed that the three groups
of CpG sites displaying changes in 5hmC are generally as-
sociated with CpG sites that undergo a loss of 5mC (Figure
2F).
With respect to the relationship of these changes to CpG
islands, most 5mC changes occurred at open sea areas for
CpG displaying slow or fast hypomethylation, whereas hy-
permethylated CpGs were additionally enriched in CpG is-
lands and shores. Consistent with previous studies (38–40),
we detected an accumulation of 5hmC at locations outside
of CpG island regions, except for group 2 of 5hmC (tran-
sient increase in 5hmC), which were enriched in CpG is-
lands (or in the near vicinity) (Figures 2C and G). The ma-
jority of CpG sites undergoing 5mC and 5hmC changes oc-
curred at promoters gene bodies in both cases, in concor-
dance with other studies (41,42) (Figure 2D and H). Ac-
cording to previous sequencing data for ESCs, 5mC and
5hmC is also abundant at enhancer regions (39). Gene on-
tology analysis of CpG sites displaying 5mC and 5hmC
changes (Figure 2I) revealed the enrichment of functional
categories associated with the inflammatory response, the
response to molecules of bacterial origin and bone remod-
eling, among others, which are related to MAC and OC bi-
ology.
Gains or losses of 5hmC positively correlates with gene ex-
pression during terminal myeloid differentiation
For genes undergoing common changes in 5mC during
MAC and OC differentiation, which make up the vast
majority, we compared the 5mC and 5hmC datasets with
the expression data, focusing on genes that underwent sig-
nificant demethylation. For genes that experienced signif-
icant changes in 5mC, we explored their gene expression,
analysing the aforementioned three groups of sequences
(group 1, genes undergoing rapid loss of 5mC; group 2,
genes undergoing slow loss of 5mC; group 3, genes display-
ing gains of methylation). Group 1–5mC genes had a pos-
itive correlation with gene expression in CpG shores and
promoters, while group 2–5mC genes displayed a positive
correlation with expression in open sea regions (Supplemen-
tary Figure S3). For group 3–5mC genes, gains of methyla-
tion at CpG sites in CpG shores, shelves, open sea regions
and gene bodies displayed a negative correlation (Supple-
mentary Figure S3A), in accordance with previous studies
(43).
In a similar way, we investigated the relationship between
5hmC changes and gene expression, considering the 5hmC
dynamics of the three groups. We observed that some sig-
nificant correlations between 5hmC and mRNA levels. For
instance, for genes in group 1–5hmC (high levels in MOs,
low in MACs/OCs) we observed a positive correlation be-
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
containing probes displaying significantmethylation changes (a total of 1157with> 0.2,P< 0.05 andFDR< 0.05) (data in Supplementary Table S3). A
scale of beta values (i.e. the ratio of the methylated probe intensity to the overall intensity, where overall intensity is the sum ofmethylated and unmethylated
probe intensities), ranging from 0 (unmethylated, blue) to 1 (completely methylated, red), is shown at the bottom. (B) Box-plots corresponding to the 5mC-
normalized data (left) and 5hmC-normalized data (right) for each of the groups presented in the heatmap in the previous section. (C) Distribution of
5mC in relation to CpG islands (CGI), including shores, shelves and open sea regions for each of the groups of CpG sites in section A. (D) Distribution
of 5mC organised by genomic location (intergenic, promoter (1500 and 200 upstream of the TSS, 5′UTR, first exon, gene body, and 3′UTR) for each of
the groups of CpG sites in section A. The darker insets within each bar indicate the number of sites annotated as enhancers. (E) Heatmap including the
5hmC data for three paired samples of MOs, MACs and OCs (D1, D2, D3) harvested on days 5 and 20. The heatmap includes all CpG-containing probes
displaying significant methylation changes (a total of 495 with  > 0.1 and P < 0.05) (data in Supplementary Table S4). A scale of beta values is shown
at the bottom. (F) Box-plots corresponding to the 5hmC-normalized data (left) and 5mC-normalized data (right) for each of the groups presented in the
heatmap in the previous section. (G) Distribution of 5hmC in relation to CpG islands (CGI), including shores, shelves and open sea regions for each of
the groups of CpG sites in section E. (H) Distribution of 5hmC organised by genomic location (intergenic, promoter 1500 and 200 upstream of the TSS,
5′UTR, first exon, gene body, and 3′UTR) for each of the groups of CpG sites in section E. The darker insets within each bar indicate the number of sites
annotated as enhancers. (I) Gene ontology (GO) enrichment analysis of CpG sites undergoing 5mC (left) or 5hmC (right) changes in differentiation to
MAC and OC.
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tween 5hmC and mRNA levels (Figure 3A, left). Looking
at CpG sites from group 3–5hmC (low levels in MOs, high
inMACs/OCs), we also observed positive correlations with
gene expression for those located in promoters and gene
bodies, as well as CpGs located in CGI shores and open sea
regions (Figure 3A, right). In all these cases, therefore, high
levels of 5hmC associate with high mRNA levels.
We further investigated the relationship between genes
with high levels of 5hmC in MOs (group1–5hmC) or in
MACs/OCs (group3–5hmC) and genes that are highly ex-
pressed inMOs andMACs/OCs. This analysis revealed the
existence of two sets of genes corresponding to key func-
tions for MOs or to the common functions in MACs/OCs
(Supplementary Table S7). For genes in group1–5hmC,
loss of 5hmC associated with decreased mRNA levels in
genes like ICAM3, CD300E and BCL6, although other
genes experienced increased expression such as ANXA2 or
CD59 (Figure 3B). For genes in group3–5hmC, increase
in expression was more robust and involved key genes as-
sociated with proper differentiation and function of OCs
(ACP5, PLD1 and S100A3) and MACs (CSF1R, MITF
and SLAMF8). Changes in 5hmC may be necessary to
maintain the high levels of core genes controlling MO and
MAC/OC function. Analysis of 5mC and 5hmC changes
of selected key genes from the different groups over time
during OC differentiation confirmed that the three dif-
ferent 5hmC dynamics (loss, transient gains, permanent
gains) were associated with loss of 5mC, although expres-
sion changes were specific to each gene, providing further
evidence that additional mechanisms ensure the specificity
for each particular gene (Figure 3B). Furthermore, upon
the inspection of the 5mC methylation status of distinct en-
hancers that fall in 5mC groups 1–3, we observed that en-
hancer hypermethylation (group 3–5mC) correlates with a
decrease in the expression of paired genes (Supplementary
Figure 3B and C), following enhancer-promoter pairing
analysis. HOMER motif analyses of differentially methy-
lated enhancers revealed the enrichment of several impor-
tant transcription factors, including those belonging to the
bZIP family, which further supports the notion that gene ex-
pression changes may require additional mechanisms (Sup-
plementary Figure 3D).
Downregulation of TET2 and TDG impairs transcriptional
activation in genes undergoing 5hmC changes as well as affect
the stability of the final phenotype
Next, we interrogated the role of TET2 and TDG in these
differentiation processes. Additional enzymes in the TET-
related pathway towards demethylation potentially involve
other TET family members and TDG (and other DNA gly-
cosylases, including MBD4). It has also been reported that
activation-induced deaminase (AID) and other related en-
zymes could deaminate 5mC and/or 5hmC (Figure 4A) (44)
followed by the participation of TDG, but this possibility is
still controversial (45). We therefore inspected the mRNA
expression levels of these enzymes in MOs and cells stimu-
lated with M-CSF and M-CSF/RANKL at 5 and 20 days
(Figure 4B). Our data confirmed that TET2 is the only gene
of the TET family expressed in these cells. Also, the gly-
cosylases TDG, MBD4, MPG, UNG or SMUG1 and the
cytidine deaminases AID, APOBEC3A, APOBEC3B and
APOBEC3F are expressed in these MOs, MACs and OCs.
Some of these enzymes have been proposed as mediators
of DNA demethylation in other contexts (7,8,46). We mea-
sured the levels of some of these proteins over time using
qRT-PCR and western blot (Figure 4C). Based on these
data and the existing literature we decided to focus on the
DNA demethylation pathway based on TET2-subsequent
oxidation followed by TDG-mediated removal and also to
explore the role of AID in active demethylation.
First, we investigated the effects of downregulating
TET2, TDG and AID on the acquisition of MAC and
OC identity and function. Interestingly, all three affected
the ability of M-CSF/RANKL-treated MOs to become
functional OCs, as demonstrated using TRAP staining and
dentin resorption assays (Figure 4D). We also showed that
these enzymes partially impair phagocytic activity and the
ability to acquire some of theMAC surface markers (Figure
4D).
Second, we tested the effects of the downregulation of the
TET2,TDG andAICDA genes on the dynamics of 5mC and
5hmC changes and the expression of genes from the differ-
ent groups, as well as the ability of MOs to correctly differ-
entiate into OCs (similar analysis was performed for MAC
differentiation, not shown). Downregulation of TET2 re-
sulted in accumulation of both 5mC and 5hmC (Figure 4E),
the latter perhaps as a result of defective further oxidation
of 5hmC to 5fC and 5caC, and a decrease in the activa-
tion of genes (Figure 4F) from the three groups with differ-
ent 5hmC dynamics. In the case of TDG siRNA-mediated
downregulation, we observed a delay in the loss of methy-
lation, possibly as a result of the defective processing of the
oxidized cytosines into abasic sites that leads to accumu-
lation of 5mC and 5hmC (Figure 4E and F). In this case,
we also observed a delay in the expression of the analyzed
genes. Interestingly, we observed a similar effect with the
siRNA for AID, although only for some of the genes (Fig-
ure 4E, F and Supplementary Figure S4B), supporting a
participation in this process.
In summary, these results suggest that TET2, TDG and,
in some cases AID, act together in the regulation of com-
mon genes in MAC and OC differentiation as well in the
acquisition of their final phenotypes.
Differential gene expression between MACs and OCs is re-
lated to differential histone modification patterns and require
prior TET2 and TDG participation in both processes
To assess the functional consequences of TET2 and TDG
in relation to differential gene expression profiling, we first
explored the CpG methylation status of genes that are dif-
ferentially expressed between both myeloid cell types.
First, with respect to the genes that are differentially
expressed between OCs and MACs (Supplementary Table
S2), we observed a significant correlation between 5mC
changes and gene expression for the indicated compar-
isons, where DNA hypomethylation or hypermethylation
associates with gene upregulation or downregulation re-
spectively (Figure 5A). The largest cell type-specific expres-
sion changes occurred during the first step of differentia-
tion (Figure 5A), and the majority of DNA methylation
Nucleic Acids Research, 2017, Vol. 45, No. 17 10011
Figure 3. Correlation between DNA hydroxymethylation signatures and gene expression during MAC and OC differentiation. (A) Scatterplots showing
the relationship between the log2FC in gene expression and the log2FC in 5hmC for all the genes which display significant 5hmC changes across the MAC
and OC differentiation. Correlation are grouped between CpG sites undergoing rapid loss of 5hmC from MOs (group 1, left) and CpG sites displaying
gains of 5hmC inMAC andOC differentiation at day 20 (group 3, right). Scatterplots are organized by genomic location [promoter (1500 and 200 upstream
of the TSS + 5′UTR + first exon) and gene body] and relation to CpG island (shore, shelf and open sea). (B) 5mC, 5hmC and gene expression dynamics of
selected CpG during monocyte-to-OC differentiation. 5mC and 5hmC are determined by the combination of bisulfite (5mC+5hmC) and oxidative bisulfite
(5mC) pyrosequencing. Quantitative RT-PCR data is normalized against RPL38. 5mC, 5hmC and gene expression data are represented with red, orange
and blue lines, respectively.
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Figure 4. TET2 and TDG regulate active DNA demethylation and gene expression in MAC and OC differentiation. (A) A schematic representation
depicting the participation of enzymes including DNA methyltransferases (DNMT1, DNMT3A and DNMT3B), methylcytosine dioxygenases (TET2),
thymine DNA glycosylases (TDG) and the base excision repair machinery (BER pathway) in the oxidation and demethylation of cytosines. (B) Gene
expression levels of several enzymes (or related family members) associated with active DNA demethylation are evaluated in MOs and differentiated
MACs and OCs at 5 and 20 days of differentiation. These enzymes are grouped as 5mC hydroxylases, cytidine deaminases, or glycosylases based on their
described activity during the demethylation process. (C) mRNA levels of AICDA, and mRNA and protein levels of TET2 and TDG are evaluated in MOs
and differentiated MACs and OCs during 20 days. Quantitative RT-PCR data is normalized against RPL38. Histone H3 and actin levels are used as a
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changes corresponded to hypomethylated CpGs (69,3%) lo-
cated at promoter regions (42,2%) but also in gene bodies
(50%) (Supplementary Table S6). This suggests that expres-
sion differences between these two cell types may depend
on the 5mC status but not necessarily related to the estab-
lishment of differential DNA methylation changes. Alter-
native mechanisms may account for differential RANKL-
mediated expression of these genes, such as regulation
of post-translational modifications of the residues of hi-
stones and chromatin structure. To explore the poten-
tial role of histone modification patterns in differentially
gene expression between both cell types, we selected sev-
eral MAC- (IL10, VSIG4, LYVE1) and OC-upregulated
(CTSK, PLD1, S100A3) genes (Figure 1 and Supplemen-
tary Table S2) and performed ChIP assays to test enrich-
ment in acetylated Lys at the N-t of histone H3 (H3Ac) in
these genes. This experiment showed that OC-specific genes
like CTSK, PLD1 or S100A3 are more enriched in H3Ac
in OCs than in MACs, whereas the opposite was observed
for MAC-specific genes like IL10, VSIG4 and LYVE1 at 20
days (Figure 5B).However, we did not observe differences in
H3Ac at day 5, corresponding with no changes in their gene
expression (Figure 1 and Supplementary Table S2). Using
ChIP-seq data from Blueprint database, we also compared
the BS-seq data and the ChIP-seq profiling of the active
chromatin marker H3K4me3 in MO,MACs and OCs, con-
firming the differential H3K4me3-enriched regions for our
differentially expressed genes in both cell types (Figure 5C
and Supplementary Figure S5).
This differential histone modification pattern is not nec-
essarily related toDNAmethylation differences between the
two cell types, although a common prior M-CSF-related
demethylation stepmay play a role in conferring the compe-
tence of these genes to acquire histone modification marks
compatible with their activation changes. To address the
question to whether active DNA demethylation machin-
ery harbour regulatory functions in histone modification
changes, we examined the effect of TET2 and TDG in hi-
stone modifications known to control gene activation such
as H3Ac or H3K4me3. We observed that either H3Ac or
H3K4me3 had differential increased levels inMACs orOCs
with respect to MOs (Figure 5) Downregulation of TET2
and TDG with siRNAs not only showed a reduction in
H3Ac and H3K4me3-enriched demethylated genes (Figure
5D) but also resulted in specific reduction in the acquisition
of expression changes at those target genes (Figure 5E).
TET2-mediated changes are required for the specific recruit-
ment of the H3K4 methyltransferase SETD1A
Finally, to investigate the specific role of TET2-mediated
changes in the subsequent recruitment of histone modifi-
cation enzymes, we decided to focus on those related to
H3K4me3, one of the two modifications previously stud-
ied. We first checked the global mRNA levels of several
H3K4 methyltransferases, namely MLL1–5, SETD1A and
SETD1B, and demethylases, including KDM1A, KDM1B
and KDM5A-D, duringMAC and OC differentiation. Fol-
lowing differentiation, we observed a downregulation of
methylases, whereas the majority of demethylases become
upregulated. Next, we mediated the knockdown of TET2
by siRNA and we observed that the majority of the H3K4
modifying enzymes remain unaffected, while only KDM1A
and KDM1B suffered a slight but significant downregula-
tion in OCs compared to MACs (Figure 6A). We then fo-
cused on the recruitment of SETD1A, the catalytic sub-
unit of the SET1/COMPASS complex which mediates bulk
methylation of H3K4 and whose binding has been reported
to be linked to TET2/3 activity (24) to selected genes
such as CTSK, PLD1 and S100A3. First, we observed that
SETD1A is indeed bound to these genes in OC and to
a lower extent in MACs. Second, we showed that TET2
knockdown impairs SETD1A binding in OCs, demonstrat-
ing the presence of TET2 is required for the recruitment of
the H3K4 methyltransferase SETD1A to mediate the ap-
propriate methylation of histones at OC-specific genes (Fig-
ure 6B).
DISCUSSION
Our results demonstrate that TET2 and TDG are essential
at least at two different levels for the acquisition of the ter-
minal myeloid phenotype, exemplified byMACandOCdif-
ferentiation. TET2 and TDG not only participate in me-
diating 5hmC and 5mC changes that are common to both
processes but also allow the subsequent occurrence of ac-
quisition of differential histone modifications at MAC- and
OC-specific genes. Differential enrichment in activating his-
tone modifications H3Ac andH3K4me3 account for differ-
ential changes in expression of some genes between MACs
and OCs. For some of these genes, we prove that a com-
mon prior demethylation event has to take place before dif-
ferential expression and histone modification profiles are
achieved. We also show that binding of H3K4 methyltrans-
ferase SETD1A to these genes depends on TET2. Also,
5hmC profiling over time reinforces the notion that this
modification is stable, and our data indicates that it has a
direct role in stabilising final myeloid identity and function.
The broad similarities between the methylomes and hy-
droxymethylomes of MACs and OCs at 5 and 20 days sug-
gest that these profiles are not directly associated with the
distinctive features of these two cell types. These data, to-
gether with the results obtained following the impact on
DNA demethylation of these cells treated with an inhibitor
of M-CSFR, indicate that changes in 5mC and 5hmC do
not depend on RANKL and that they can be attributed
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
loading control in the western blot. (D) The effects of siRNA-mediated downregulation of TET2, TDG and AID are evaluated in OCs and MACs. TRAP
staining and dentin resorption assays (left panels) are performed in OCs after 20 days of differentiation. Phagocytosis assays and FACS analyses of surface
markers, including CD163, CD206, MSR1, CD11b and CD33 (right panels) are performed in MACs after 5 days of differentiation. (E) Effects of TET2,
TDG andAID downregulation on 5mC and 5hmC in OC differentiated during 20 days. Percentage of 5mC and 5hmC are evaluated in ANXA2, TM4SF19
andADAM12 following siRNAdownregulation of TET2 (upper rows), TDG (third row) andAID (lower row). (F) Analyses of gene expression ofANXA2,
TM4SF9 and ADAM12 by RT-qPCR following siRNA downregulation of TET2 (upper row), TDG (middle row) and AID (lower row). Relative mRNA
is normalized against RPL38.
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Figure 5. Relationship between TET2 and TDG participation and activating histone marks in MAC and OC differentiation. (A) Scatter plots depicting
the correlations of 5mC and gene expression for the comparisons of MAC and OC versus MOs at 5 and 20 days of differentiation. Solid lines indicate
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solely to M-CSF. Despite the absence of 5mC and 5hmC
differences between MACs and OCs, our data supports the
essential role of TET2 and TDG in the acquisition of ex-
pression changes that will lead to the generation of the
differentiated phenotypes. Data by Michael Rehli and col-
leagues (27) previously proved the essential role of TET2
in demethylation processes from human monocytes. In this
study, we show how TDG and AID are also determinant
for the acquisition of key expression changes to yield the
final phenotype. The participation of AID in active DNA
demethylation has been controversial in the past few years
(44,45), and it has been reported to involve the deamina-
tion of 5mC and 5hmC. In this respect, our data suggest a
participation of AID in this process, although the detailed
participation and gene specificity require further analysis.
Given that MACs and OCs display around 16.4% of dif-
ferences in their expression profiles, this therefore suggests
that alternative mechanisms, other than DNAmethylation,
are involved in their establishment. In our study, we prove
that histone modifications are associated with the existence
of differential expression of genes becoming demethylated.
It is interesting to highlight thatmany of these genes that are
differentially expressed between MACs and OCs undergo
demethylation at a similar extent. In our study, we prove
that demethylation of these genes leads to a competent
state that is then sensitive to further epigenetic mechanisms
in MACs and OCs, such as histone modifications. Addi-
tional mechanisms, like microRNA-mediated control may
also play a part in differential gene expression. In fact, we
have recently shown that NF-B, downstream of RANKL,
mediates the control of several microRNAs essential for OC
andMAC differentiation (47). Our results provide evidence
of the participation of active DNA demethylation machin-
ery, focusing on TET2 and TDG, in determining changes
not only inDNAmethylation, but also in the recruitment of
differential histone-modifying enzymes duringMACorOC
differentiation. Previous studies have shown that TET pro-
teins can interact indirectly with histonemodifying complex
SET1/COMPASS by promoting the OGT-mediated Glc-
NAcylation of the subunit HCF1 of the complex, favouring
binding of SETD1A methyltransferase to chromatin and
modulating H3K4me3 and subsequent transcriptional ac-
tivation (24). We here prove that SETD1A binding to genes
that demethylated and specifically expressed in OCs depend
on TET2.
Other studies have shown that TDG interacts with ac-
tivating histone modifiers such as MLL or CBP/p300 to
maintain active H3K4me2-enriched chromatin states dur-
ing cell differentiation, and preventing the gain of repres-
sive H3K27 andH3K9 trimethylation and subsequent tran-
scriptional silencing (26,48). Also, in OC differentiation,
it has been reported that RANKL stimulates the recruit-
ment of chromatin modifiers such as EZH2 or Jmjd3 to
mediate H3K27 methylation changes in OC-specific genes
(49,50). The selective TET2- and TDG-mediated recruit-
ment of histone-modifying enzymes to target particular ge-
nomic regions suggests a specific mechanism that will need
further investigation. Of note, RANKL-mediated regula-
tion in modulating histone modifications relies not only on
promoting genes that aremore actively transcribed, but also
on preventing activating histone marks to those genes that
are upregulated in MAC differentiation such as IL10.
Furthermore, our results support the role of 5hmC as
a stable epigenetic mark. This has been previously re-
ported using stable isotope labeling of cytosine derivatives
in the DNA of mammalian cells and ultrasensitive tandem
liquid-chromatography mass spectrometry (16). However,
our analysis represents the first report of the dynamics of
these changes in immune cell differentiation. A significant
proportion of the genes displaying high levels of 5hmC in
MOs, which are rapidly lost during MAC and OC differ-
entiation, encode for factors necessary for MOs. In addi-
tion, genes that undergo permanent gains of 5hmC dur-
ing MAC and OC differentiation encode for key factors for
both MACs and OCs. In this context, hydroxymethylation
changes appear to account for core functions of MOs and
these differentiated cells. Gain or loss of 5hmC could play a
regulatory function through specific recruitment of 5hmC-
binding proteins or 5hmC readers recently identified (19)
that may promote transcription and chromatin accessibil-
ity.
Our findings shed light on the multiple roles of TET2
and TDG in determining the acquisition of the final phe-
notype on myeloid cells. We have demonstrated a direct role
in the activation of genes that are commonly upregulated in
two terminal differentiation processes. In addition, we prove
that a common TET2- and TDG-mediated demethylation
step is required to allow the participation of subsequent
differential epigenetic mechanisms that will determine the
specific activation of MAC- and OC-specific genes. In these
divergent processes, the activeDNAdemethylationmachin-
ery can direct RANKL-dependent histonemodification, af-
fecting specific cell type-specific gene transcription and con-
tributing to the final phenotype.
ACCESSION NUMBERS
Methylation array and expression array data for this pub-
lication have been deposited in the NCBI Gene Expression
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the tendency and r and p values are annotated. (B) ChIP assays showing the levels of histone H3Ac in selected genes that display differential levels of
expression between MACs and OCs and undergo DNA demethylation in MACs or OCs. IgG (grey bar) was used as a negative control. Data is shown as
relative enrichment of the bound fraction with respect to the input DNA. Data is represented as mean values of four independent experiments ± SEM.
Statistically significant tests are represented as *P<0.05 and **P<0.01. Corresponding 5mC DNA methylation is depicted as a dotted graph and data
were obtained as described in Figure 2. (C) Examples showing methylation and H3K4me3 binding pattern (ChIPseq data from BluePrint) at the region
neighbouring selected hypomethylated CpGs. The CpG displaying differential methylation (Illumina probe) between MO andMAC/OC is marked with a
green bar. (D) Quantitative ChIP assays showing the effects of TET2- and TDG-silencing on H3K4me3 and H3Ac enrichment to hypomethylated genes
in MACs and OCs. (E) Effects of TET2 and TDG downregulation on expression of H3Ac and H3K4me3-enriched regions that become demethylated and
reached higher expression in OC (CTSK, PLD1, S100A3) or MAC (IL10). Data in D and E represent mean values ± SEMwith three biological triplicates
and significant tests are represented as *P < 0.05.
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Figure 6. Effects of TET2 silencing on the expression and recruitment of
H3K4 methyltransferases. (A) Gene expression analyses by qRT-PCR of
several H3K4 methyltransferases (MLL1–5, SETD1A and SETD1B) and
demethylases (KDM1A, KDM1B, KDM5A-D) following siRNA silenc-
ing of TET2 in MAC and OC at day 20 of differentiation. Gene expres-
sion was normalized against RPL38 and a non-targeting siRNA was used
as control. Expression of each gene was normalized against its expression
in monocytes, indicated by the dotted line. (B) ChIP analyses of the re-
cruitment of SETD1A to OC-specific genes, namely CSTK, PLD1 and
S100A3, in MAC and OC differentiated for 20 days upon TET2 silencing
with siRNA.A non-targeting siRNAwas used as a control and enrichment
was compared to non-specific IgG binding. Experiments were performed
as biological triplicates and significant tests are indicated as *P< 0.05 and
**P < 0.01.
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